Literature DB >> 33723998

Acridones Are Highly Potent Inhibitors of Toxoplasma gondii Tachyzoites.

P Holland Alday1, Erin V McConnell1, Jan M Boitz Zarella1, Rozalia A Dodean1, Papireddy Kancharla2, Jane X Kelly1,2, J Stone Doggett1.   

Abstract

Acridone derivatives, which have been shown to have in vitro and in vivo activity against Plasmodium spp, inhibit Toxoplasma gondii proliferation at picomolar concentrations. Using enzymatic assays, we show that acridones inhibit both T. gondii cytochrome bc1 and dihydroorotate dehydrogenase and identify acridones that bind preferentially to the Qi site of cytochrome bc1. We identify acridones that have efficacy in a murine model of systemic toxoplasmosis. Acridones have potent activity against T. gondii and represent a promising new class of preclinical compounds.

Entities:  

Keywords:  acridone; cytochrome bc1; dihydroorotate dehydrogenase; drug discovery; toxoplasma

Year:  2021        PMID: 33723998      PMCID: PMC8273083          DOI: 10.1021/acsinfecdis.1c00016

Source DB:  PubMed          Journal:  ACS Infect Dis        ISSN: 2373-8227            Impact factor:   5.084


  26 in total

1.  Insertional mutagenesis and marker rescue in a protozoan parasite: cloning of the uracil phosphoribosyltransferase locus from Toxoplasma gondii.

Authors:  R G Donald; D S Roos
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

2.  Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-hydroxyquinolones in Toxoplasma gondii.

Authors:  Jana Hegewald; Uwe Gross; Wolfgang Bohne
Journal:  Mol Biochem Parasitol       Date:  2013-06-05       Impact factor: 1.759

Review 3.  Toxoplasma gondii: from animals to humans.

Authors:  A M Tenter; A R Heckeroth; L M Weiss
Journal:  Int J Parasitol       Date:  2000-11       Impact factor: 3.981

4.  Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii.

Authors:  Barbara A Fox; David J Bzik
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

5.  De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii.

Authors:  Barbara A Fox; David J Bzik
Journal:  Nature       Date:  2002-02-21       Impact factor: 49.962

6.  Genetic Evidence for Cytochrome b Qi Site Inhibition by 4(1H)-Quinolone-3-Diarylethers and Antimycin in Toxoplasma gondii.

Authors:  P Holland Alday; Igor Bruzual; Aaron Nilsen; Sovitj Pou; Rolf Winter; Choukri Ben Mamoun; Michael K Riscoe; J Stone Doggett
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii.

Authors:  Lorraine Jones-Brando; E Fuller Torrey; Robert Yolken
Journal:  Schizophr Res       Date:  2003-08-01       Impact factor: 4.939

8.  In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.

Authors:  Pascale Meneceur; Marie-Anne Bouldouyre; Dominique Aubert; Isabelle Villena; Jean Menotti; Virginie Sauvage; Jean-François Garin; Francis Derouin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

9.  Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.

Authors:  Papireddy Kancharla; Rozalia A Dodean; Yuexin Li; Sovitj Pou; Brandon Pybus; Victor Melendez; Lisa Read; Charles E Bane; Brian Vesely; Mara Kreishman-Deitrick; Chad Black; Qigui Li; Richard J Sciotti; Raul Olmeda; Thu-Lan Luong; Heather Gaona; Brittney Potter; Jason Sousa; Sean Marcsisin; Diana Caridha; Lisa Xie; Chau Vuong; Qiang Zeng; Jing Zhang; Ping Zhang; Hsiuling Lin; Kirk Butler; Norma Roncal; Lacy Gaynor-Ohnstad; Susan E Leed; Christina Nolan; Frida G Ceja; Stephanie A Rasmussen; Patrick K Tumwebaze; Philip J Rosenthal; Jianbing Mu; Brett R Bayles; Roland A Cooper; Kevin A Reynolds; Martin J Smilkstein; Michael K Riscoe; Jane X Kelly
Journal:  J Med Chem       Date:  2020-05-26       Impact factor: 7.446

10.  Biochemical and molecular characterization of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase from Toxoplasma gondii.

Authors:  Miryam Andrea Hortua Triana; My-Hang Huynh; Manuel F Garavito; Barbara A Fox; David J Bzik; Vern B Carruthers; Monika Löffler; Barbara H Zimmermann
Journal:  Mol Biochem Parasitol       Date:  2012-05-08       Impact factor: 1.759

View more
  3 in total

1.  Structure-activity relationships of Toxoplasma gondii cytochrome bc1 inhibitors.

Authors:  P Holland Alday; Aaron Nilsen; J Stone Doggett
Journal:  Expert Opin Drug Discov       Date:  2022-08-08       Impact factor: 7.050

2.  Targeting the Ubiquinol-Reduction (Qi) Site of the Mitochondrial Cytochrome bc1 Complex for the Development of Next Generation Quinolone Antimalarials.

Authors:  Kangsa Amporndanai; Nattapon Pinthong; Paul M O'Neill; W David Hong; Richard K Amewu; Chandrakala Pidathala; Neil G Berry; Suet C Leung; Stephen A Ward; Giancarlo A Biagini; S Samar Hasnain; Svetlana V Antonyuk
Journal:  Biology (Basel)       Date:  2022-07-25

3.  Inhibition of Toxoplasma gondii by 1,2,4-triazole-based compounds: marked improvement in selectivity relative to the standard therapy pyrimethamine and sulfadiazine.

Authors:  Lidia Węglińska; Adrian Bekier; Nazar Trotsko; Barbara Kaproń; Tomasz Plech; Katarzyna Dzitko; Agata Paneth
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.